Literature DB >> 20077524

Toxicity of nanomaterials to the eye.

Tarl W Prow1.   

Abstract

What do nanoparticles offer drug delivery to the eye that traditional formulations do not? The underlying concept of nanomedicine is that the nanomaterials have properties that their constituent components do not have. These unique properties are the benefit, but the cost can be more a complicated toxicology assessment. Ocular delivery of therapeutic nanoparticles has the potential to greatly increase the quality of life through maintaining our vision. The eye is composed of multiple tissue types, i.e., epithelium, muscle, immune cells, neural cells, and blood vessels, to name a few. Ocular diseases affect many of these tissues at once. Introduce novel therapeutic nanoparticles and determining mechanisms of toxicity becomes challenging. This review is a survey of what is known about toxicity in experimental nanoparticles for ocular therapeutics. Specific cases are chosen to illustrate a range of toxic effects of nanoparticles in the eye. There is a unique research opportunity for in-depth toxicology studies of nanoparticles in the eye. This has been made possible by the rapid development of therapeutic nanoparticles in the last few years. Copyright (c) 2009 John Wiley & Sons, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20077524     DOI: 10.1002/wnan.65

Source DB:  PubMed          Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol        ISSN: 1939-0041


  15 in total

Review 1.  Nanomedicine in the application of uveal melanoma.

Authors:  Shuo You; Jing Luo; Hans E Grossniklaus; Ma-Ling Gou; Ke Meng; Qing Zhang
Journal:  Int J Ophthalmol       Date:  2016-08-18       Impact factor: 1.779

2.  Gold nanoparticles disrupt zebrafish eye development and pigmentation.

Authors:  Ki-Tae Kim; Tatiana Zaikova; James E Hutchison; Robert L Tanguay
Journal:  Toxicol Sci       Date:  2013-04-02       Impact factor: 4.849

Review 3.  Recent overview of ocular patents.

Authors:  Ripal J Gaudana; Mitan R Gokulgandhi; Sai H S Boddu; Ashim K Mitra
Journal:  Recent Pat Drug Deliv Formul       Date:  2012-08

Review 4.  Nanoparticles for drug delivery to the anterior segment of the eye.

Authors:  Dileep R Janagam; Linfeng Wu; Tao L Lowe
Journal:  Adv Drug Deliv Rev       Date:  2017-04-06       Impact factor: 15.470

Review 5.  Antimicrobial nanomedicine for ocular bacterial and fungal infection.

Authors:  Wenjie Fan; Haijie Han; Yaoyao Chen; Xiaobo Zhang; Yifan Gao; Su Li; Qiao Jin; Jian Ji; Ke Yao
Journal:  Drug Deliv Transl Res       Date:  2021-04-11       Impact factor: 4.617

6.  Successfully improving ocular drug delivery using the cationic nanoemulsion, novasorb.

Authors:  Frederic Lallemand; Philippe Daull; Simon Benita; Ronald Buggage; Jean-Sebastien Garrigue
Journal:  J Drug Deliv       Date:  2012-02-27

Review 7.  Nanocarriers for ocular drug delivery: current status and translational opportunity.

Authors:  Srividya Gorantla; Vamshi Krishna Rapalli; Tejashree Waghule; Prem Prakash Singh; Sunil Kumar Dubey; Ranendra N Saha; Gautam Singhvi
Journal:  RSC Adv       Date:  2020-07-24       Impact factor: 4.036

8.  Eye irritation testing of nanomaterials using the EpiOcular™ eye irritation test and the bovine corneal opacity and permeability assay.

Authors:  Susanne N Kolle; Ursula G Sauer; Maria C Rey Moreno; Wera Teubner; Wendel Wohlleben; Robert Landsiedel
Journal:  Part Fibre Toxicol       Date:  2016-04-15       Impact factor: 9.400

Review 9.  Advanced drug delivery and targeting technologies for the ocular diseases.

Authors:  Jaleh Barar; Ayuob Aghanejad; Marziyeh Fathi; Yadollah Omidi
Journal:  Bioimpacts       Date:  2016-03-30

10.  The Neuroprotective and antioxidative effects of submicron and blended Lycium barbarum in experimental retinal degeneration in rats.

Authors:  Jen-Shuai Chang; Yih-Jing Lee; David A Wilkie; Chung-Tien Lin
Journal:  J Vet Med Sci       Date:  2018-05-11       Impact factor: 1.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.